The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Cidara Therapeutics Common Stock 171757107 3,337 444,965 SH   SOLE   444,965 0 0
CymaBay Therapeutics Common Stock 23257D103 1,737 301,477 SH   SOLE   301,477 0 0
Dicerna Pharmaceuticals Common Stock 253031108 708 223,457 SH   SOLE   223,457 0 0
Egalet Common Stock 28226B104 6,849 2,889,926 SH   SOLE   2,889,926 0 0
ESSA Pharma Common Stock 29668H104 933 1,696,969 SH   SOLE   1,696,969 0 0
FibroGen Common Stock 31572Q808 20,268 627,492 SH   SOLE   627,492 0 0
Jounce Therapeutics Common Stock 481116101 8,132 579,650 SH   SOLE   579,650 0 0
Juno Therapeutics Common Stock 48205A109 36,750 1,229,512 SH   SOLE   1,229,512 0 0
Nabriva Therapeutics Common Stock G63637105 11,937 1,139,035 SH   SOLE   1,139,035 0 0
Paratek Pharmaceuticals Common Stock 699374302 62,670 2,600,410 SH   SOLE   2,600,410 0 0
Pieris Pharmaceuticals Common Stock 720795103 6,918 1,367,253 SH   SOLE   1,367,253 0 0